Mayne Pharma Group Ltd
Company Profile
Business description
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercialising branded women's health and dermatology pharmaceuticals, offering patients better, safer, and more accessible medicines. The Company has a product development and manufacturing facility in Salisbury, Australia, with expertise in the formulation of complex oral and topical dose forms, including modified-release products and poorly soluble compounds. Its segments are Women's Health, Dermatology and International. The Women's Health segment generates maximum revenue and distributes branded products in the US, including NEXTSTELLIS, ANNOVERA, IMVEXXY, and BIJUVA. The Company generates maximum revenue from the United States.
Contact
1538 Main North Road
Salisbury South
SalisburySA5106
AUST: +61 882092666
Sector
Healthcare
Stock type
Defensive
Industry
Medical Distribution
Fiscal Year End
Employees
160
Mayne Pharma Group Ltd News & Analysis
stocks
Mayne Pharma woes to persist for 2020
stocks
How the Morningstar Best Ideas list did in 2019
stocks
Scott and Josh take note: our strategic assets are off limits
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,260.90 | 40.40 | 0.44% |
| CAC 40 | 8,312.25 | 22.25 | -0.27% |
| DAX 40 | 26,013.07 | 245.04 | -0.93% |
| Dow JONES (US) | 53,185.90 | 374.09 | -0.70% |
| FTSE 100 | 10,756.91 | 67.35 | -0.62% |
| HKSE | 25,329.73 | 237.26 | -0.93% |
| NASDAQ | 26,370.89 | 31.54 | -0.12% |
| Nikkei 225 | 66,215.34 | 96.59 | -0.15% |
| NZX 50 Index | 13,786.90 | 130.40 | -0.94% |
| S&P 500 | 7,686.14 | 0.00 | 0.00% |
| S&P/ASX 200 | 9,066.70 | 41.70 | 0.46% |
| SSE Composite Index | 3,979.89 | 6.41 | -0.16% |